136 related articles for article (PubMed ID: 28235241)
1. Impact of CXCR4/CXCL12 Blockade on Normal Plasma Cells In Vivo.
Moore N; Moreno Gonzales M; Bonner K; Smith B; Park W; Stegall M
Am J Transplant; 2017 Jun; 17(6):1663-1669. PubMed ID: 28235241
[TBL] [Abstract][Full Text] [Related]
2. CXCR4-CXCL12 interaction is important for plasma cell homing and survival in NZB/W mice.
Cheng Q; Khodadadi L; Taddeo A; Klotsche J; F Hoyer B; Radbruch A; Hiepe F
Eur J Immunol; 2018 Jun; 48(6):1020-1029. PubMed ID: 29427452
[TBL] [Abstract][Full Text] [Related]
3. Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates.
Rossi AP; Tremblay S; Castro-Rojas CM; Burg AA; Roskin KM; Gehman JM; Rike-Shields A; Alloway RR; Brailey P; Allman D; Hildeman DA; Woodle ES
Am J Transplant; 2023 Jun; 23(6):759-775. PubMed ID: 36871629
[TBL] [Abstract][Full Text] [Related]
4. Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
Lecavalier-Barsoum M; Chaudary N; Han K; Pintilie M; Hill RP; Milosevic M
Br J Cancer; 2019 Jul; 121(3):249-256. PubMed ID: 31239542
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
Dillmann F; Veldwijk MR; Laufs S; Sperandio M; Calandra G; Wenz F; Zeller J; Fruehauf S
Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.
Juarez J; Dela Pena A; Baraz R; Hewson J; Khoo M; Cisterne A; Fricker S; Fujii N; Bradstock KF; Bendall LJ
Leukemia; 2007 Jun; 21(6):1249-57. PubMed ID: 17410186
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
10. Plasma cell dynamics in the bone marrow niche.
Benet Z; Jing Z; Fooksman DR
Cell Rep; 2021 Feb; 34(6):108733. PubMed ID: 33567286
[TBL] [Abstract][Full Text] [Related]
11. A critical role of Src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the ischemic heart.
Cheng M; Huang K; Zhou J; Yan D; Tang YL; Zhao TC; Miller RJ; Kishore R; Losordo DW; Qin G
J Mol Cell Cardiol; 2015 Apr; 81():49-53. PubMed ID: 25655934
[TBL] [Abstract][Full Text] [Related]
12. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
[TBL] [Abstract][Full Text] [Related]
13. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the CXCL12/CXCR4 axis prevents periurethral collagen accumulation and lower urinary tract dysfunction in vivo.
Macoska JA; Wang Z; Virta J; Zacharias N; Bjorling DE
Prostate; 2019 May; 79(7):757-767. PubMed ID: 30811623
[TBL] [Abstract][Full Text] [Related]
16. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1.
Fiorina P; Jurewicz M; Vergani A; Petrelli A; Carvello M; D'Addio F; Godwin JG; Law K; Wu E; Tian Z; Thoma G; Kovarik J; La Rosa S; Capella C; Rodig S; Zerwes HG; Sayegh MH; Abdi R
J Immunol; 2011 Jan; 186(1):121-31. PubMed ID: 21131428
[TBL] [Abstract][Full Text] [Related]
17. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
18. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.
Katoh H; Hosono K; Ito Y; Suzuki T; Ogawa Y; Kubo H; Kamata H; Mishima T; Tamaki H; Sakagami H; Sugimoto Y; Narumiya S; Watanabe M; Majima M
Am J Pathol; 2010 Mar; 176(3):1469-83. PubMed ID: 20110411
[TBL] [Abstract][Full Text] [Related]
19. CXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activity.
Cheng M; Zhou J; Wu M; Boriboun C; Thorne T; Liu T; Xiang Z; Zeng Q; Tanaka T; Tang YL; Kishore R; Tomasson MH; Miller RJ; Losordo DW; Qin G
Circ Res; 2010 Oct; 107(9):1083-93. PubMed ID: 20847314
[TBL] [Abstract][Full Text] [Related]
20. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
